Features of the clinical course of hupertrophic cardiomyopathy in children with onset in the first year of life against the background of mutations in sarcomeric and RAS-associated genes

Authors: Fetisova S.G., Melnik O.V., Sitnikova K.A., Fomicheva Yu.V., Sokolnikova P.S., Vershinina T.L., Fedorova O.V., Pervunina T.M., Kostareva A.A., Vasichkina E.S.

Download

References
About the authors

References

Lipshultz S.E., Sleeper L.A., Towbin J.A., Lowe A.M., Orav E.J., Cox G.F. et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 2003; 348 (17): 1647–1655. DOI: 10.1056/NEJMoa021715
Karim S., Chahal C.A.A., Sherif A.A., Khanji M.Y., Scott C.G., Chamberlain A.M. et al. Re-evaluating the incidence and prevalence of clinical hypertrophic cardiomyopathy: An Epidemiological Study of Olmsted County, Minnesota. Mayo Clin Proc. 2024; 99 (3): 362–374. DOI: 10.1016/j.mayocp.2023.09.009
Marston N.A., Han L., Olivotto I., Day S.M., Ashley E.A., Michels M. et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur. Heart J. 2021; 42 (20): 1988–1996. DOI: 10.1093/eurheartj/ehab148
Norrish G., Kolt G., Cervi E., Field E., Dady K., Ziółkowska L. et al. Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Heart Fail. 2021; 8 (6): 5057–5067. DOI: 10.1002/ehf2.13573
Chan W., Yang S., Wang J., Tong S., Lin M., Lu P. et al. Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: a multicentre retrospective cohort study. EClinicalMedicine. 2022; 49: 101466. DOI: 10.1016/j.eclinm.2022.101466
Limongelli G., Monda E., Tramonte S., Gragnano F., Masarone D., Frisso G. et al. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 2020; 299: 186–191. DOI: 10.1016/j.ijcard.2019.06.073
Stegeman R., Paauw N.D., de Graaf R., van Loon R.L.E., Termote J.U.M., Breur J.M.P.J. The etiology of cardiac hypertrophy in infants. Sci Rep. 2021; 11 (1): 10626. DOI: 10.1038/s41598-021-90128-3
Boleti O., Norrish G., Field E., Dady K., Summers K., Nepali G. et al. Natural history and outcomes in paediat- ric RASopathy-associated hypertrophic cardiomyopathy. ESC Heart Fail. 2024; 11 (2): 923–936. DOI: 10.1002/ehf2.14637
Chen H., Li X., Liu X., Wang J., Zhang Z., Wu J. et al. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort. Orphanet J. Rare Dis. 2019; 14 (1): 29. DOI: 10.1186/s13023-019-1010-z
Kauffman H., Ahrens-Nicklas R.C., Calderon-Anyosa R.J.C., Ritter A.L., Lin K.Y., Rossano J.W. et al. Genotype-phenotype association by echocardiography offers incremental value in patients with Noonan Syndrome with multiple lentigines. Pediatr. Res. 2021; 90 (2): 444–451. DOI: 10.1038/s41390-020-01292-7
Lioncino M., Monda E., Verrillo F., Moscarella E., Calcagni G., Drago F. et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail. Clin. 2022; 18 (1): 19–29. DOI: 10.1016/j.hfc.2021.07.004
Kaski J.P., Syrris P., Esteban M.T., Jenkins S., Pantazis A., Deanfield J.E. et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ. Cardiovasc. Genet. 2009; 2 (5): 436–441. DOI: 10.1161/CIRCGENETICS.108.821314
Field E., Lopes L.R., Dady K., Kaski J.P. Early Childhood-onset hypertrophic cardiomyopathy in a family with an in-frame MYH7 deletion. Circ. Genom. Precis. Med. 2022; 15 (4): e003667. DOI: 10.1161/CIRCGEN.121.003667
Kadirrajah V., Acquaah V., Norrish G., Field E., Dady K., Cervi E. et al. Clinical characterisation of hypertrophic cardiomyopathy caused by MYH7 gene variants in children. Eur. Heart J. 2021; 42 (1). DOI: 10.1093/eurheartj/ehab724.1774
Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015; 17 (5): 405–424. DOI: 10.1038/gim.2015.30
Monda E., Prosnitz A., Aiello R., Lioncino M., Norrish G., Caiazza M. et al. Natural history of hypertrophic cardiomyopathy in Noonan Syndrome with multiple lentigines. Circ. Genom. Precis. Med. 2023; 16 (4): 350–358. DOI: 10.1161/CIRCGEN.122.003861
Calcagni G., Adorisio R., Martinelli S., Grutter G., Baban A., Versacci P. et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies. Heart Fail. Clin. 2018; 14 (2): 225–235. DOI: 10.1016/j.hfc.2017.12.005
Faienza M.F., Meliota G., Mentino D., Ficarella R., Gentile M., Vairo U. et al. Cardiac phenotype and gene mutations in RASopathies. Genes (Basel). 2024; 15 (8): 1015. DOI: 10.3390/genes15081015
Calcagni G., Limongelli G., D'Ambrosio A., Gesualdo F., Digilio M.C., Baban A. et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int. J. Cardiol. 2017; 245: 92–98. DOI: 10.1016/j.ijcard.2017.07.068
Zenker M. Clinical overview on RASopathies. Am. J. Med. Genet. C. Semin. Med. Genet. 2022; 190 (4): 414–424. DOI: 10.1002/ajmg.c.32015
Gazzin A., Fornari F., Niceta M., Leoni C., Dentici M.L., Carli D. et al. Defining the variant-phenotype correlation in patients affected by Noonan syndrome with the RAF1:c.770C>T p.(Ser257Leu) variant. Eur. J. Hum. Genet. 2024; 32 (8): 964–971. DOI: 10.1038/s41431-024- 01643-6
Cerrato F., Pacileo G., Limongelli G., Gagliardi M.G., Santoro G., Digilio M.C. et al. A standard echocardiographic and tissue Doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. Cardiol. Young. 2008; 18 (6): 575–580. DOI: 10.1017/S104795110800320X
Naneishvili T., Yuan M., Mansour M., Moody W.E., Steeds R.P. Dysplastic mitral valve in Costello Syndrome. JACC Case Rep. 2024; 29 (14): 102408. DOI: 10.1016/j.jaccas.2024.102408
Marino B., Gagliardi M.G., Digilio M.C., Polletta B., Grazioli S., Agostino D. et al. Noonan syndrome: structural abnormalities of the mitral valve causing subaortic obstruction. Eur. J. Pediatr. 1995; 154 (12): 949–952. DOI: 10.1007/BF01958636
Zhang N., Chen L., Zhang J. Septal myectomy for severe neonatal hypertrophic cardiomyopathy caused by PTPN11 gene mutation: a case report. Biomed. J. Sci. Tech. Res. 2019; 4: 1–3. DOI: 10.26717/BJSTR.2019.21.003544
Faienza M.F., Giordani L., Ferraris M., Bona G., Cavallo L. PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link? Pediatr. Cardiol. 2009; 30 (7): 1012–1015. DOI: 10.1007/s00246-009-9473-7
Liu S., Zhao Y., Mo H., Hua X., Chen X., Wang W. et al. Genetic variations in PTPN11 lead to a recurrent left ventricular outflow tract obstruction phenotype in childhood hypertrophic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2024; 169 (1): 197–207. DOI: 10.1016/j. jtcvs.2024.06.012
Nguyen S.N., Chung M.M., Vinogradsky A.V., Richmond M.E., Zuckerman W.A., Goldstone A.B. et al. Long-term outcomes of surgery for obstructive hypertrophic cardiomyopathy in a pediatric cohort. JTCVS Open. 2023; 16: 726–738. DOI: 10.1016/j.xjon.2023.09.032
Kaltenecker E., Schleihauf J., Meierhofer C., Shehu N., Mkrtchyan N., Hager A. et al. Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy. Cardiovasc. Diagn. Ther. 2019; 9 (Suppl. 2): S299–S309. DOI: 10.21037/cdt.2019.05.01

About the authors

Svetlana G. Fetisova, Junior Researcher, Pediatric Cardiologist; ORCID
Olesya V. Melnik, Cand. Med. Sci., Senior Researcher; ORCID
Kseniya A. Sitnikova, Resident Physician; ORCID
Yuliya V. Fomicheva, Laboratory Geneticist; ORCID
Polina S. Sokolnikova, Laboratory Geneticist; ORCID
Tatyana L. Vershinina, Head of Pediatric Cardiology and Medical Rehabilitation Department; ORCID
Olga V. Fedorova, Head of Grant Competition Support Group; ORCID
Tatyana M. Pervunina, Dr. Med. Sci., Director of Institute of Perinatology and Pediatrics, Chief of Chair of Perinatology and Pediatrics, Institute of Medical Education; ORCID
Anna A. Kostareva, Dr. Med. Sci., Director of Institute of Molecular Biology and Genetics, Associate Professor of Chair of Internal Medicine, Institute of Medical Education; ORCID
Elena S. Vasichkina, Dr. Med. Sci., Chief Researcher, Head of Research Center for Unknown, Rare and Genetically Determined Diseases, Professor of Chair of Perinatology and Pediatrics, Institute of Medical Education; ORCID

Chief Editor

Konstantin V. Shatalov
MD, PhD, DSc, Professor
Bakoulev National Medical Research Center for Cardiovascular Surgery

Sort by

Если вы заметили опечатку, выделите текст и нажмите alt+A